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Late-phase clinical trials investigatingmetformin as a
cancer therapy are underway. However, there re-
mains controversy as to the mode of action of met-
formin in tumors at clinical doses. We conducted a
clinical study integrating measurement of markers
of systemic metabolism, dynamic FDG-PET-CT,
transcriptomics, and metabolomics at paired time
points to profile the bioactivity of metformin in pri-
mary breast cancer. We show metformin reduces
the levels of mitochondrial metabolites, activates
multiple mitochondrial metabolic pathways, and in-
creases 18-FDG flux in tumors. Two tumor groups
are identified with distinct metabolic responses, an
OXPHOS transcriptional response (OTR) group for
which there is an increase in OXPHOS gene
transcription and an FDG response group with
increased 18-FDG uptake. Increase in proliferation,
as measured by a validated proliferation signature,Cell Metabolism 28, 679–688, Novemb
This is an open access article undsuggested that patients in the OTR group were resis-
tant to metformin treatment. We conclude that mito-
chondrial response to metformin in primary breast
cancer may define anti-tumor effect.
INTRODUCTION
Metformin can reduce proliferation of cancer cell lines in vitro and
in vivo, and this effect has been ascribed to inhibition of mito-
chondrial complex 1 (Wheaton et al., 2014). However, the doses
of metformin used have typically been 10- to 1,000-fold greater
than peak plasma level in humans (Dowling et al., 2012). Hence
controversy remains as to whether metformin’s effects on tumor
metabolism at clinical doses are determined by its direct effects
onmitochondria or through its action on systemicmetabolism via
AMPK-dependent inhibition of hepatic gluconeogenesis and
subsequent reduced circulating glucose and insulin levels.
Several window trials have used immunohistochemistry to
investigate metformin’s clinical effects in breast, endometrial,
and prostate cancer. A number have shown that metforminer 6, 2018 Crown Copyright ª 2018 Published by Elsevier Inc. 679
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Trial Design and Imaging Analysis
(A) Study design. Shortly after diagnosis, patients with untreated primary breast cancer received 13–21 days of slow release metformin at escalating dose levels
(500 mg for days 1–3, 1,000 mg for days 4–6, and 1,500 mg thereafter) with core biopsies taken pre- and post-metformin before proceeding to neoadjuvant
chemotherapy.
(B) Change in the FDG flux constant KFDG-2cpt of the primary tumor in individual patients (left panel) and overall (lower right panel) pre- and post-metformin (n = 36,
paired t test; data shown are means ± SEM). Upper right panel: static PET-CT images in coronal plane pre- and post-metformin are from an individual with an
increase in KFDG-2cpt following metformin; note increased uptake in axillary lymph nodes (circled).
(C) Median fold change and interquartile range for metabolites pre- and post-metformin. Metabolites with statistically significant absolute change on Wilcoxon
signed rank test are shown in red with p values (n = 29).
See also Figure S1 and Tables S1–S3.can reduce the proliferation marker Ki67, but no singular mech-
anism has been clearly demonstrated. Activation of AMPK sug-
gestive of an energy stress has been observed, while other
studies have demonstrated reduced pAKT consistent with
decreased insulin signaling (Dowling et al., 2015; Hadad et al.,
2011; Schuler et al., 2015). Recently published work by Liu
et al. comparing the metabolite profile of ten ovarian tumor sam-
ples from patients on metformin versus ten control samples (pa-
tients not on metformin) demonstrated decreases in the levels of
some TCA cycle intermediates and short-chain acyl-carnitines.
In addition, the response tometformin seen in the humanmetab-
olite profiles could be recapitulated in amousemodel and in vitro
when nutrient concentrations were limited (Liu et al., 2016). To
date, this is the most convincing clinical evidence that metformin
has significant andmeasurablemitochondrial effects at standard
therapeutic doses. Here, we present the results of a clinical study
that integrates tumor metabolomic profiling with dynamic imag-
ing, transcriptomics, and systemic metabolic markers to further
dissect the effects of metformin on systemic and breast tumor
metabolism.680 Cell Metabolism 28, 679–688, November 6, 2018We recruited 40 female patients with treatment-naive primary
breast cancer to the study. Before and after a 13- to 21-day
course of metformin, patients underwent a dynamic fluoro-
deoxy-D-glucose positron emission tomography-computed to-
mography (FDG-PET-CT) scan, breast core biopsies from the
primary tumor under ultrasound guidance, and blood samples
to assay host metabolic markers of the insulin axis (Figure 1A).
See Table S1 for details of study entry criteria and Table S2 for
tumor features. See Supplemental Information for further detail.
RESULTS AND DISCUSSION
Metformin Increases FDG Flux into Primary Breast
Tumors
Pre-clinical data have shown that inhibition of oxidative phos-
phorylation (OXPHOS) by metformin increases dependence on
glycolysis (Ben Sahra et al., 2010; Birsoy et al., 2014; Wheaton
et al., 2014). The FDG radio-tracer is a marker of tissue glucose
utilization. Kinetics analysis of FDG uptake time courses ob-
tained from dynamic PET images potentially provides more
consistent measures of tumor tracer uptake, adjusted for varia-
tions in tracer inflow to the tumor, than standard static FDG-
PET-CT (Dunnwald et al., 2011). Using an irreversible two-tissue
compartment model describing rates of FDG transport and
phosphorylation (STAR Methods), we observed an increase in
FDG flux (KFDG) into the primary breast cancer following metfor-
min (Figure 1B) but no change in the static uptake measures
SULmax and SULmean for tumor (standardized uptake values
normalized for lean body mass) (Figures S1A and S1B; Table
S3). There was no change in nodal SULmax for patients with
FDG avidity within ipsilateral axillary lymph nodes (Figure S1C).
There was a significant correlation between change in KFDG in
the primary tumor and change in SULmax in the axillary nodes
(Figure S1D).
The above findings infer that metformin treatment leads to
increased glucose uptake by breast tumors and this would be
consistent with a switch to glycolytic metabolism. In addition,
the analysis emphasizes the sensitivity of dynamic FDG-PET
over static scanning in identifying subtle pharmacodynamic
changes in glucose metabolism. If normal tissues such as liver
absorbed more FDG in response to metformin, FDG activity
concentrations in the blood would fall, potentially reducing
FDG uptake by the tumor. However, the compartment model/
flux constant approach describes tumor FDG uptake after allow-
ing for differences across the whole time course of the dynamic
scan in levels of blood-borne tracer flowing into the tumor, deter-
mined from imaged activity concentrations in the descending
aorta. It is possible that it is precisely because this model con-
trols for the flow of tracer into the tumor that we see a significant
change in the flux constant and not standardized uptake values
on static PET scanning.
Two Tumor Groups with Distinct Metabolic Responses
to Metformin
We did not observe changes in the levels of the TCA cycle inter-
mediates citrate, succinate, fumarate, and malate in contrast to
Liu et al. (2016), or aspartate, a key marker of electron transport
chain integrity (Figure 1C). Ornithine is condensed with carba-
moyl phosphate to produce citrulline in the only intra-mitochon-
drial reaction of the urea cycle and citrulline levels decreased
(mean log2FC = 0.53; p = 0.007). Some investigators have
observed an increase in the ADP/ATP and AMP/ATP ratios typi-
cally under in vitro nutrient-deprived conditions but there was no
significant increase in intratumoral ADP/ATP or AMP/ATP ratios
post-metformin (Figure S1E), and this is consistent with metab-
olomic data from ovarian tumors published in Liu et al. (2016).
The discordance in findings with metabolomic profiling from
pre-clinical studies may reflect the heterogeneity inherent in a
study analyzing clinical samples and the difficulty of making
very precise measurements when there may be only small
changes in the levels of these metabolites. Mitochondrial
dysfunction under the tissue culture conditions described in
the literature cited above is likely to be greater than in our study.
Indeed, Gaude et al. (2018) showed that, at lower levels of mito-
chondrial dysfunction, there was little or no decrease in TCA cy-
cle metabolites and aspartate. Uptake from the stroma in an
in vivo system may help maintain aspartate levels (for example,
Birsoy et al., 2015 used a cell line lacking in the transporter
SLC1A3, which was expressed at the mRNA level in our clinicalsamples). In contrast to findings in some other studies (Dowling
et al., 2015; Hadad et al., 2011) tumor immunohistochemistry
demonstrated no change in AMPK phosphorylation following
metformin (paired t test, p = 0.801) (Figure S1F). There was no
correlation between change in pAMPK and change in KFDG
(Figure S1G).
Whole-transcriptome RNA sequencing pre- and post-metfor-
min revealed significant upregulation of several pathways linked
to metabolism (Figure 2A) and more specifically to mitochondrial
pathways and disease (Table S4). This included four KEGGpath-
ways that we predicted would be targeted by metformin based
on extensive pre-clinical data (Birsoy et al., 2014; Fendt et al.,
2013; Liu et al., 2016; Mullen et al., 2011; Wheaton et al.,
2014): oxidative phosphorylation (KEGG:00190); TCA cycle
(KEGG:00020); glycolysis and gluconeogenesis (KEGG:00010);
and alanine, aspartate, and glutamate metabolism
(KEGG:00250). Taking all genes that were significantly up- or
downregulated from these pathways we observed that for one
hierarchical cluster of patients fold change in expression was
strikingly increased for this set of genes (OXPHOS responders
or OTR [OXPHOS transcriptional response]). All patients in the
OTR group were estrogen receptor-positive (Figure 2B).
Coherent with this observation, unsupervised hierarchical clus-
tering of the expressed nuclear whole transcriptome showed
that patients in the OTR group also clustered together in this
analysis (Figure S2A). Notably, clustering of the OTR group
also occurred for expressed genes of the mitochondrial tran-
scriptome (Figure S2B). For patients with limited OTR there
was evidence of increased glucose uptake defined by an in-
crease in KFDG (FDG responders or FR) in contrast to the
OTR group.
Consistent with mitochondrial targeting it has recently been
shown that metformin treatment leads to a decrease in the levels
of short-chain acyl-carnitines in ovarian cancer (Liu et al., 2016).
Metabolomic profiling of paired pre- and post-metformin sam-
ples showed that acetyl- and propionylcarnitine levels decrease
(mean log2FC =1.32, p = 0.046 and log2FC =1.01, p = 0.039,
respectively). Acetylcarnitine is a short-chain acyl-carnitine
derived from glucose carbons (Schooneman et al., 2013) and,
in contrast to the OTR group, their FR counterparts were able
to maintain acetylcarnitine levels (Figure 2C). There was a strong
correlation between change in KFDG and change in acetylcarni-
tine levels (Figure 2D). Figure S2C shows the interquartile range
and median fold change for metabolites in the OTR and FR
groups. It is unclear why intratumoral acetylcarnitine levels drop-
ped, and this finding is at odds with Chen et al. (2016), who
showed that complex 1 inhibition in a cell line model resulted
in a severalfold increase in acetylcarnitine levels within whole
cells and mitochondria. However, this may be due to the discor-
dance between the very different environmental conditions and
strength of mitochondrial inhibition in our clinical study
compared with cell line models. In addition, Chen et al. only as-
sayed the mitochondrial matrix, and used a different complex 1
inhibitor in a non-breast cancer model. Notably, carnitine o-ace-
tyltransferase, which catalyzes the bidirectional conversion of
acetylcarnitine to acetyl-coenzyme A (CoA) within both mito-
chondria and peroxisomes, was differentially upregulated in
the OTR group (all Figure 3A). Hence, we speculate that altered
flux in this pathway may be a consequence of metforminCell Metabolism 28, 679–688, November 6, 2018 681
Figure 2. Metformin Alters Levels of Mitochondrial Metabolites and Increases OXPHOS Relevant Gene Transcription in a Subset of Patients
(A and B) Circos plot to show all significantly upregulated metabolic pathways in the KEGG database. The width of the outer and inner circles show the mean
relative abundances for the broadest hierarchy and secondary hierarchy. The bars in the innermost circle represent the mean relative abundances for genes
encoding proteins within the individual pathways. The curved lines link genes that are shared among different pathways as indexed by KEGG (A). Heatmap of
differentially expressed genes from the following KEGG pathways: oxidative phosphorylation (KEGG:00190); TCA cycle (KEGG:00020); glycolysis and gluco-
neogenesis (KEGG:00010); alanine, aspartate, and glutamate metabolism (KEGG:00250). Each row represents a gene and each column represents a single
patient (n = 36). Colors reflect the fold change for each gene post-metformin: red, upregulation; blue, downregulation. Samples were visually clustered using
hierarchical clustering. OXPHOS transcriptional response (OTR) and FDG response (FR) groups shown. Shown below is heatmap of change in significantly
altered metabolites and KFDG-2cpt (all post minus pre) for same individual patients (B).
(C) Scatterplot to show for the OTR and FR groups change in KFDG-2cpt and acetylcarnitine levels for the breast primary tumor (both post minus pre). Data shown
are means ± SEM, unpaired t test.
(D) Correlation between change in KFDG-2cpt and acetylcarnitine (both post minus pre). Spearman’s rank correlation coefficient and significance are shown.
See also Figure S2 and Table S4.treatment. The positive correlation between change in FDG
flux and intratumoral acetylcarnitine levels possibly reflects
increased flux of glucose carbons toward acetyl-CoA. To fully
understand the effects of metformin and mitochondrial defects682 Cell Metabolism 28, 679–688, November 6, 2018on acyl-carnitine metabolism will require further work in pre-clin-
ical models.
Maintaining aspartate levels has been shown to be a key resis-
tance mechanism to electron transport chain inhibition and
(legend on next page)
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biguanides (Birsoy et al., 2015; Cardaci et al., 2015; Sullivan
et al., 2015). There was no difference in aspartate metabolite
levels between the FR and OTR groups (Figures 1C and S3A).
However, several genes involved in aspartate metabolism were
significantly upregulated and it was striking that the increase in
expression of three of the five genes that encode for units of
the malate-aspartate shuttle (GOT2, MDH1, and MDH2) was
significantly greater in the OTR group compared with the FR
group (Figure 3A). Dependency on glutamine as a source of cit-
rate for either lipid or aspartate biosynthesis has been shown to
be a key resistance mechanism to metformin and other mito-
chondrial insults (Birsoy et al., 2015; Fendt et al., 2013; Mullen
et al., 2011) and we observed increased expression of multiple
genes that regulate glutaminemetabolism. Two key checkpoints
in this process were differentially upregulated in the OTR group,
mitochondrial isocitrate dehydrogenase (IDH2) and the citrate
transporter, SLC25A1, which delivers glutamine-derived citrate
to the cytosol where it is cleaved by ATP citrate lyase to oxaloac-
etate and acetyl-CoA for aspartate and lipid synthesis, respec-
tively (Figure 3A). Previous work has also shown that both
isoforms of isocitrate dehydrogenase, IDH1 and IDH2, support
growth in cells that use glutamine-dependent reductive carbox-
ylation. Hence, tumors harboring IDH mutations may be more
susceptible to biguanide therapy.
Systemic Response to Metformin Does Not Correlate
with Change in Intratumoral Assays
Metformin has been shown to modulate a number of systemic
metabolic and inflammatory markers in diabetic populations. In
our study metformin lowered circulating levels of serum glucose,
insulin, c-peptide, and an insulin resistance score (homeostatic
model assessment or HOMA), but not leptin, adiponectin,
C-reactive protein, tumor necrosis factor a, or interleukin-6 (Fig-
ures 3B and S3B; Table S5). However, there were no significant
differences between the OTR and FR groups in pre-/post-met-
formin changes in levels of any of these circulating metabolic
markers (Figure S3C). There was a marked overlap in genes
whose change in expression correlated with change in KFDG
and change in acetylcarnitine (hypergeometric test,
p < 0.00001), but little corresponding overlap with genes related
to change in c-peptide, glucose, insulin, or HOMA (Figures 3C
and S3D). Eighteen of the genes correlating with change in
KFDG and acetylcarnitine were KEGG-annotated metabolism
genes most notably associated with oxidative phosphorylation,
carbohydrate, amino acid, and nucleotide metabolism pathways
(Table S6). There was an increase in pAKT expression on tumor
immunohistochemistry (paired t test, p = 0.026), but no correla-
tion between change in pAKT expression and change in c-pep-Figure 3. Effect of Metformin on Systemic Metabolism
(A) Change in expression of genes involved in regulation of aspartate/malate shutt
are means ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
(B) Pre- and post-metformin serum glucose, insulin, insulin growth factor-1 level
metabolic marker, p value shown (paired t test, n = 40).
(C) Venn diagram to show overlap of all genes whose change in expression corr
KFDG-2cpt or tumor acetylcarnitine.
(D and E) Correlation between peak serummetformin levels (2 hr post dose) and tu
pre) and GLUT1 expression (log2FC) for the breast primary tumor (E). Spearman
See also Figure S3 and Tables S5 and S6.
684 Cell Metabolism 28, 679–688, November 6, 2018tide, glucose, insulin, or HOMA, and no significant difference
between the FR and OTR groups (Figures S3E–S3G). There
was also no difference in pAMPK expression between the FR
and OTR groups (Figure S3G).
The increase in tumor pAKT expression was unexpected and
not consistent with a decrease in insulin receptor signaling or
findings in prior studies. AKT activation increases ATP levels in
cells and has been identified in a number of studies as being a
key player in the regulation of both glycolysis and oxidative
phosphorylation (Robey andHay, 2009). Recent work has shown
that mitochondrial AKT activation occurs in the context of tumor
energy and hypoxic stress, switching metabolism toward glycol-
ysis (Chae et al., 2016). However, we cannot exclude metfor-
min’s systemic effects on host metabolism being a significant
factor in modulating tumor metabolism and proliferation, and
indeed we would expect a decrease in insulin levels to have
some effect on tumor intracellular signaling. Our study only re-
cruited patients with normal systemic glucose levels, and for pa-
tients with diabetes or glucose intolerance any effect on insulin
signaling via the hypoglycemic activity of metformin is likely to
be greater.
We then investigated the relationship between tumor metfor-
min levels and metabolic response. Although serum and tumor
levels were significantly correlated with each other (Figure 3D)
they did not differ between the OTR and FR groups (Figure S4A).
Previously published pre-clinical data suggested that expression
of the organic cation transporter, OCT1 (encoded by gene
SLC22A1), is required for tumor uptake of metformin and meta-
bolic response (Chandel et al., 2016; Dowling et al., 2016). There
was no significant correlation between baseline OCT1 gene
expression and tumor metformin levels but notably the patient
with highest tumor metformin levels also had the greatest
expression of tumor OCT1 (Figure S4B). Furthermore, there
was no difference in baseline OCT1 expression between the
OTR and FR groups (Figure S4C). Baseline OCT1 expression
did correlate with change in KFDG, although the relevance of
this finding is unclear given that there was no such relationship
with tumor metformin levels (Figure S4D).
Glucose transporter gene expression may determine the
sensitivity of cell lines to biguanides (Birsoy et al., 2014). Expres-
sion of the glucose transporter, GLUT1 (encoded by gene
SLC2A1), has previously been shown to correlate with uptake
of FDG on PET-CT (Bos et al., 2002), and in our study change
in KFDG positively correlated with the change in expression of
GLUT1 (Figure 3E). However, there was no significant difference
in GLUT1 expression between the two groups although there
was for another glucose transporter, GLUT4 (encoded by gene
SLC2A4) (Figure S4E).le and oxidative and reductive metabolism, unpaired t test (n = 36). Data shown
s, and HOMA score for individual patients. Significant decrease for each host
elated with either change in systemic levels of circulating c-peptide or tumor
mor metformin levels (D). Correlation between change in KFDG-2cpt (post minus
’s rank correlation coefficient and significance are shown for (D) and (E).
Figure 4. Effect of Metformin on Proliferation
Left panel: heatmap of genes from the proliferation signature. Each row represents a gene and each column represents a single patient. Colors reflect the fold
change for each gene post-metformin: red, upregulation; blue, downregulation. Samples were visually clustered using hierarchical clustering. Right upper panel:
pre- and post-metformin expression of signatures for individual patients (n = 36); right lower panel, scatterplot to show change in expression of signatures for the
OTR and FR groups. Data shown are means ± SEM, unpaired t test (n = 36).OTR to Metformin Relates to Change in a Proliferation
Metagene
Several clinical studies have shown that metformin can reduce
breast, prostate, and endometrial cancer cell proliferation (Ha-
dad et al., 2011; Joshua et al., 2014; Laskov et al., 2014; Mitsu-
hashi et al., 2014; Niraula et al., 2012; Schuler et al., 2015). We
explored the effect of metformin on a validated human breastcancer proliferation signature (Desmedt et al., 2008) and overall
observed no significant change following metformin treatment
(Figure 4). However, it was striking that an increase in metagene
expression occurred in the OTR group, while, in contrast, there
was a decrease for several patients in the FR group, the change
in metagene expression consequently differing significantly be-
tween the two groups (Figure 4). Under in vitro low-glucoseCell Metabolism 28, 679–688, November 6, 2018 685
conditions the ability for cell lines to upregulate OXPHOS pre-
dicts for sensitivity to biguanides (Birsoy et al., 2014), and our
data suggest that a reactive increase in OXPHOS and aspartate
synthesis gene transcription may be critical for resistance to
metformin. None of the circulating or tumor immunohistochem-
ical markers, metformin levels, KFDG, or significantly altered me-
tabolites correlated with change in expression of the proliferation
metagene (Figure S4F).
Conclusion and Perspectives
Our work outlines two types of breast cancer metabolic
response to metformin and links the effects of metformin on
mitochondrial metabolism with its effects on breast cancer pro-
liferation at a transcriptional level. Tumors that were able to up-
regulate OXPHOS gene transcription in response to metformin
showed an increase in their proliferation score suggestive of
resistance following metformin treatment.
The upregulation of multiple transcriptomic pathways involved
in mitochondrial metabolism and decrease in levels of several in-
tratumoral mitochondrial metabolites is suggestive of metformin
interfering with mitochondrial metabolism. Furthermore, the
increased expression of multiple genes regulating glycolysis
and glucose transport alongside our imaging data is consistent
with mobilization of glucose metabolism in response to metfor-
min. The upregulation of key regulatory genes for glycolysis,
aspartate, and glutamine metabolism in response to metformin
may represent a mechanism of resistance and confirms the
potential of previously proposed strategies to target these path-
ways, for example, by combining biguanideswith glutaminase in-
hibitors or dichloroacetate (Fendt et al., 2013; Haugrud et al.,
2014). Estrogen receptor expressionmay also act as a biomarker
to distinguish the two types of metabolic response. Among the
most likely determinants for resistance in our view are mitochon-
drial defects (for example, mutations in complex 1 genes), and
this would be consistent with in vitro data (Birsoy et al., 2014).
Hence, we propose that translational work within ongoing phase
3 trials should investigate whether mitochondrial mutations her-
ald biguanide sensitivity and clinical outcome. However, we
emphasize that early dynamicmonitoring of responsemaydetect
the heterogeneity that cannot be detectable at baseline.
There have been a number of other window studies designed
to assess metformin’s pharmacodynamic effects in several
different tumor types and it is important to note the differences
to this study. Most of these trials have used immunohistochem-
ical approaches on a wide range of markers, but in particular
Ki67, AMPK, and markers of apoptosis with discrepant results
(Dowling et al., 2015; Hadad et al., 2011; Schuler et al., 2015).
The most in-depth clinical study to date to use metabolomic ap-
proaches, Liu et al. (2016), suggested some evidence of mito-
chondrial interference but, in contrast to our study, did not
take serial biopsies to allow identification of differential types
of response and was limited to effectively one assay. In addition,
Liu et al. assayed samples taken from ten patients with ovarian
cancer who happened to be receiving metformin for diabetes
while using control samples from non-diabetic patients with a
lower mean bodymass index. Hence, this was a comparison be-
tween two patient groups with distinct host metabolism (Liu
et al., 2016). In contrast, this study only recruited from a non-dia-
betic population, the focus of ongoing phase 3 trials.686 Cell Metabolism 28, 679–688, November 6, 2018These data are consistent with several of the observations
seen previously using in vitro and in vivo models but it is still un-
certain whether these perturbations are enough for metformin to
deliver clinical benefit to patients. A recent substudy of the
ALTTO phase 3 adjuvant breast cancer trial reported a strong as-
sociation between metformin and improved overall survival in
diabetic patients (Sonnenblick et al., 2017). Our observations
make the case for the continued clinical study of metformin
and more potent biguanides (Zhang et al., 2016) in non-diabetic
patients. The results of ongoing phase 3 trials are awaited (Gilles-
sen et al., 2016; Goodwin et al., 2015).
Limitations of Study
This study had no control arm and hence it is possible that some
of the observations could be related to the passage of time or
interventions (e.g., biopsies). Given the nature of this clinical
translational study the analysis especially relies on correlative
evaluation and hence we cannot rule out a link between the sys-
temic effects of metformin and significant changes in tumor
metabolism and proliferation. Although 40 patients are a sub-
stantial number for an involved pharmacodynamic study of this
type, correlations across the assays were not able to be carried
out across the full cohort for varied reasons (technical difficulties
with some scans and insufficient sample to carry out all assays,
etc.) and increased recruitment would provide greater power for
the analyses.
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METHOD DETAILS
Clinical Study Design and Patient Selection
Patients were recruited from themedical oncology breast cancer clinic over a period of 30months betweenMay 2011 and November
2013 in three UK centres, Oxford, Luton and Dundee. Informed consent was obtained from all patients. The study was prospectively
approved by the NHS Oxfordshire Research Ethics Committee A and registered with the ClinicalTrials.gov identifier: NCT01266486.
All patients at the point of recruitment had been referred with a view to neoadjuvant chemotherapy, had histologically confirmed
breast cancer and gave informed consent. In all cases the primary breast cancer was in situ and no patients had received any prior
treatment for breast cancer. See Table S1 for a list of key eligibility criteria. In total 41 patients were recruited and had evaluable data.
See Table S2 for numbers of patients with sufficient data for paired analysis for each assay. All patients were female and the median
age at study entry was 49 years (range 27 – 67 years). Median body mass index at study entry was 28.1 (range 19.6 – 45.3).
Metformin was given in the Glucophage XR formulation in an escalating dose once daily for a minimum of 13 days and a maximum
of 21 days (500mg for days 1–3, 1000mg for days 4–6 and 1500mg thereafter). The day prior to commencingmetformin a core biopsy
was taken under ultrasound guidance from the periphery of the primary tumour. Within 1minute of this procedure the biopsymaterial
was snap frozen in liquid nitrogen prior to storage at -80C. Prior to metabolomics analysis biopsy samples were divided and one
portion used for broad metabolomics analysis and the other to generate a lipid profile.
PET-CT Protocol
The radiotracer, 2-deoxy-2-(18F)fluoro-D-glucose (18[F]-FDG), was used for all examinations. Prior to scanning, patients were fasted
overnight for at least 8 hours but could drink water. Patients’ blood glucose was checked just prior to the scan with a portable blood
glucosemonitor to ensure it was <7mmol/L. All scans took place on either a 3Dmode time of flight GEDiscovery 690 64-slice PET-CT
system (GE Healthcare, Milwaukee) or Siemens Biograph mCT-128 (Siemens Healthcare, Germany).
A dynamic acquisition of the breast tumour (and any lymph nodes within the PET field of view) was initiated with the patient imaged
supine. Patients were injected with 18[F]-FDG (3 MBq/kg, up to a maximum of 400 MBq) 30 seconds into PET imaging, whichCell Metabolism 28, 679–688.e1–e4, November 6, 2018 e1
continued for 45 minutes. The 45 minutes of data were then reconstructed as a sequence of images describing average activity con-
centrations during a series of time frames (1x30s, 12x5s, 6x10s, 5x30s, 10x60s, 6x300s).
50 minutes after injection, a static PET scan was performed from skull base to mid-thigh, acquiring data for four minutes at each
bed position. Thus the primary breast cancer was scanned at approximately 60minutes post injection, in addition to the dynamic PET
scanning from 0-45 minutes. Prior to each PET acquisition a CT scan was performed for localization and PET attenuation correction,
using a pitch of 0.984, 120 kV, automA with a noise index of 25.
The PET images were reconstructed on a matrix of 5.535.533.3 mm3 voxels using filtered back projection for the dynamic
sequence, and iterative reconstruction for the static scan. See Supplemental Information for further details of static and kinetic anal-
ysis of imaging.
Static PET-CT Analysis
Tumour volumes were delineated on the 60-minute static FDG-PET scans by a nuclear medicine radiologist working on a
Hermes workstation and using Hybrid viewer software (Hermes Medical Solutions AB, Stockholm, Sweden). Maximum and
mean standardized uptake values (SUV) within each tumour volume were normalized by lean body mass (LBM) and reported as
SULmean=SUVmean*LBM/BW and SULmax=SUVmax*LBM/BW respectively, where
LBMHume =

0:32810 3 BW + 0:33929 3 H 3 29:5336 ðMalesÞ
0:29569 3 BW + 0:41813 3 H3 43:2933 ðFemalesÞ
and BW and H are the body weight in kg and height in cm (Hume, 1966).
Dynamic PET-CT Analysis
The tumour volume contoured on a static PET-CT image was transferred to the corresponding 0-45 minute dynamic FDG-PET scan
by co-registering the two image sets. Time-activity curves (TACs) describing time-courses of mean tumour FDG activity concentra-
tion within the tumour were then calculated for the tumour regions of the dynamic scans. Time-courses of blood-borne tracer con-
centrations were similarly obtained from regions defined in the descending aorta (average 42 ± 4 slices with mean volume of 32 ±
11 cm3), and used to describe tracer inflow into tumours (‘input functions’, IF).
Kinetic analysis of tumour FDG uptake was carried out for 36/40 patients, using irreversible 2- and 3-tissue compartment models
(Bertoldo et al., 2001). Tumour TACS for the remaining four patients were not analysed as they showed pronounced discontinuities,
likely due to movement during scanning. The compartment models characterize FDG transport and intracellular phosphorylation us-
ing a small number of parameters, and enable modelled tumour TACs to be calculated directly from IFs. The models were fitted by
adjusting the parameters to achieve the best weighted least-squares match between modelled and measured tumour TACs
(Liu et al., 2014).
The 2-tissue compartment model (2cpt) provided better descriptions of tumour TAC data, judged by the Akaike and Bayesian in-
formation criteria (AIC and BIC) used alongside a runs-test. From each fit, estimated values and associated statistical uncertainties
were obtained for the model parameters vB, K1, k2 and k3, which respectively describe the fractional tumour blood volume and rate-
constants for FDG transport back and forth between the vasculature and tumour cells, and for intra-cellular phosphorylation. Uncer-
tainties on these fitted parameters are quite large due to statistical noise in dynamic PET images. Flux constants KFDG, numerically
equal to K1k2/(k2+k3), were also calculated. Conceptually KFDG describes the rate of intra-cellular FDG phosphorylation when a
steady-state unit concentration of FDG exists in the blood, and statistically it is estimated substantially more precisely than the in-
dividual model rate-constants. Figure S5 summarizes the analysis. Significances of differences in model parameters before and after
metformin were assessed using paired t-test and Wilcoxon signed rank test. Only changes in KFDG proved significant.
It was not useful to kinetically analyse FDG uptake time-courses in the axillary nodes, since the small nodal volumes led to a high
degree of noise on the time-courses and fitted kinetics parameters including the flux constant. All patients included in the axillary
node analysis who had lymph node avidity had evidence at pre-treatment biopsy or surgery of metastatic breast carcinoma involve-
ment within the axillary nodes with the exception of 3 patients for whom no biopsy or surgical data was available.
Mass Spectrometry Analysis of Clinical Samples for Metabolomic Profile
Breast cancer tissue was pulverised via mechanical disruption (IKA Ultra-Turrax T-8 homogenizor) prior to hydrophilic extraction of
intracellular metabolites from tissue using a methanol/acetonitrile/water (50/30/20) extraction solution (250 mL of extraction solution
per 10mg homogenised tissue). Following thorough mixing, the samples were centrifuged for 10 minutes at 10,000G and the super-
natant stored at -80C prior to mass spectrometry analysis.
For the LC separation, column A the sequant Zic-pHilic (150 mm3 2.1 mm i.d. 5 mm) with the guard column (20 mm3 2.1 mm i.d.
5 mm) from HiChrom, Reading, UK. Mobile phase A: 20 mM ammonium carbonate plus 0.1% ammonia hydroxide in water. Mobile
phase B: acetonitrile. The flow rate was kept at 180 mL/minute and gradient as follow: 0–1 minutes 70% of B, 16 minutes 38% of B,
16.5 minutes 70% of B, 25 minutes 70% of B. The mass spectrometer (Thermo Q-Exactive Orbitrap) was operated in a polarity
switching mode. Experimenters analysing samples frommetabolomics experiments were blinded to the experimental interventions.
Samples were randomised in order to avoid machine drifts.e2 Cell Metabolism 28, 679–688.e1–e4, November 6, 2018
Analysis of RNASeq Data
Next generation sequencing of ‘Poly (A) targeted’ mRNA, including library preparation, was carried out by the Oxford Genomics
Centre core facility at theWelcome Trust Centre for HumanGenetics. TheNEBNextmRNA Library PrepMasterMix Set (NewEngland
Biolabs) was used for preparation of the expression libraries and the Illumina HiSeq 2000 system used to carry out the sequencing.
Paired-read were aligned to human reference genome GRCh38, including transcriptomic information, by Bowtie 2.2.6 and Tophat
v2.1. The fold change of normalized expression level, FPKM (Fragments Per Kilobase of transcript per Million mapped reads), for
each gene was then estimated from those aligned reads using Cuffdiff 2.2.1. Non-parametric rank product (R package and version)
was used to discover the genes with consistent statistically significant fold change (probability of false positive < 0.05) between pre-
and post-metformin treatment, among all patients were selected. This approach was preferred with respect to EdgeR (Anders and
Huber, 2010) and Deseq (McCarthy et al., 2012; Robinson et al., 2010) as in datasets with high variability and paired samples (pre and
post- treatment) non parametric methods tend to work better in our previous studies (Mehta et al., 2016); however analysis with
EdgeR (version 3.16.5) and Deseq (version 1.26.0) was also done and did not change the main conclusions.
Measurement of Circulating Markers
Patient serum samples were collected after fasting overnight just prior to the breast core biopsy (and for the post-metformin sample 2
hours post-dose). Fasting glucose, insulin, c-peptide, c-reactive protein, leptin and adiponectin weremeasured using NHS biochem-
istry services to standardised and validated protocols. The homeostasis model assessment (HOMA) was calculated using the
following equation: (glucose mmol/L * insulin mU/L)/22.5.
IL-6 and TNF-alpha were measured in duplicate by High Sensitivity enzyme linked immunosorbent assay (ELISA) (Invitrogen).
These assays utilise two amplification steps, allowing for the detection of low levels of cytokines present in serum and plasma
samples.
Immunohistochemistry
Staining for p-AMPK (1 in 200, thr172 residue, Cell Signaling Technologies #2535) and pAKT (1 in 100, ser473 residue, Cell Signaling
Technologies #4060), was performed on a Leica Bond-max autostainer in the GCP laboratory, Department of Pharmacology, Uni-
versity of Oxford. For pAMPK, cell pellet controls were generated using MCF7 cells treated with either 20 mMCompound C (negative
control) or 250 mMAICAR (positive control) for 24 hours prior to harvesting. For pAKT, cell pellet controls were generated using serum
starved MCF7 cells either untreated (negative control) or treated with IGF-1 (positive control) for 30 minutes prior to harvesting and
the generation of a formalin fixed, paraffin embedded cell pellet block.
Quantitative scoring of the staining of complete tumour sections was evaluated by two accredited pathologists using high power
fields the intensity of the immunostaining was classified into 4 categories: 0, no immunostaining present; 1, weak staining; 2, mod-
erate staining; and 3, strong staining and the percentage of positive cells at each intensity was then classified into 4 groups; 1 (0-10%
positive cells), 2 (11% to 50% positive cells), 3 (51% to 80% positive cells) or 4 (81 to 100% positive cells). The H-score of immuno-
reactivity was obtained by multiplying the intensity and percentage scores.
QUANTIFICATION AND STATISTICAL ANALYSIS
Processing for dynamic PET-CT and gene expression profiling are reported above. Absolute difference in metabolites was analysed
using paired non-parametric method (Wilcoxon Signed Rank Sum). All other differences in measurements pre- and post-metformin
were compared using paired t-tests. Correlation analyses between gene expression scores, metabolites, metformin levels, circu-
lating metabolic markers and KFDG were performed using non-parametric methods (Spearman’s rank correlation coefficient). Differ-
ences inmeasurements between theOTR and FR groupswere examined using an unpaired two-tailed t-test. Statistical tests for each
analysis are defined in figure legends. In all cases a p-value <0.05 was considered significant. Analysis of RNASeq and Metabolomic
data was carried out using non-parametric approaches and hence the data was not required to follow an underlying distribution.
Kinetic model fits to the tumour TACs extracted from dynamic PET scans were runs-tested as a non-parametric check on fit quality.
Significances of pre/post metformin differences in PET tracer kinetics parameters and normalised static uptake values were as-
sessed using a parametric t-test and a non-parametric Wilcoxon signed rank test, the assumption of normally-distributed data un-
derlying the t-test being rejectable with p<.05 for all variables except K1 according to the Shapiro-Wilk test. Statistical packages,
GraphPad PRISM v6.0, R v3.3.1 and Matlab were used for analyses.
Sample Size Estimation
Based on our and others’ previous analyses of microarray data, a minimum of 20 cases with paired measurements at two time points
were estimated to be sufficient to observe expression changes of at least 1.7-fold in genes showing a coefficient of variation at each
time point up to 50% with a significance level after multiple test correction of p=0.05 (taking into account filtering of not expressed
transcripts) and an 80% power. This estimate assumed uniformity of drug response. However, double the number was desirable for
higher significance and considering correlation with baseline expression and response.Cell Metabolism 28, 679–688.e1–e4, November 6, 2018 e3
DATA AND SOFTWARE AVAILABILITY
The RNASeq gene expression data reported in this paper have been reported in Mendeley data with address http://dx.doi.org/10.
17632/cytrpb62f2.1.
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